ABBVIE

NImmune Biopharma partners with BioTherapeutics to develop precision medicines in inflammation and immunology, leveraging BioTherapeutics' preclinical services and regulatory expertise, enhancing NImmune's capabilities in precision immunology.

NImmune Biopharma partners with BioTherapeutics to develop precision medicines for inflammation and immunology, leveraging BioTherapeutics’ preclinical services and regulatory expertise, including animal models and computational tools for autoimmune and inflammatory diseases.

AbbVie seeks a Manager of Clinical Trial Strategy and Submission to deliver global clinical development regulatory strategies and operations for designated compounds. Responsibilities include managing CTA strategies, ensuring compliance with global regulations, interfacing with regulators, and maintaining regulatory databases. Qualifications include a degree in life sciences, 6+ years in the pharmaceutical industry, and extensive global clinical trial experience. The role can be based remotely within the US.

JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.

Ubrelvy (ubrogepant) showed 73% more effectiveness in reducing migraine disability within 2 hours compared to placebo in a clinical trial, potentially improving quality of life for migraine sufferers.

ORIC-944 is an orally bioavailable PRC2 inhibitor designed to improve solubility and stability, with a longer half-life than EZH2 inhibitors. It reprograms AR-independent prostate tumors to AR-dependent states.

D.A.A.V. and C.J.W. hold patents on LAG-3, with potential income from licensing. D.A.A.V. has multiple roles in biotech firms and receives funding from BMS and Novasenta. E.J.W. advises and holds stock in several biotech companies. A.H.S. has patents on the PD-1 pathway, receives research funding, and serves on various advisory boards. A.R.C. consults for Abound Bio.

Alector presented baseline characteristics for the INVOKE-2 Phase 2 trial of AL002 at AAIC® 2024, a global trial evaluating AL002's safety and efficacy in early Alzheimer’s disease. AL002, a TREM2 agonist, aims to slow disease progression. The trial enrolled 381 participants with early AD, with baseline characteristics confirming the intended population. Treatment-emergent brain MRI changes resembling ARIA were observed, leading to early discontinuation of homozygous APOE e4 carriers. Results are expected in Q4 2024.

Frontier Medicines achieved a milestone payment in its AbbVie partnership, advanced lead candidates targeting an undruggable transcription factor, appointed Gerardo Ubaghs as CFO, secured a $20M Series C extension, presented new data for FMC-376 at AACR, and announced an oversubscribed $80M Series C financing.

AbbVie received a Complete Response Letter from the FDA for ABBV-951, a treatment for motor fluctuations in advanced Parkinson's disease, due to observations during inspection of a third-party manufacturer. The CRL does not raise issues on safety, efficacy, or labeling of ABBV-951.